1. Novel Approaches in T1D Management

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Background

5. HbA1c and Weight in Patients With T1D in the United States

6. Hypoglycemia in Patients With T1D

7. Pramlintide for the Treatment of T1D

8. An Unmet Need Non-Insulin Therapies for T1D

9. Determining the Safety and Efficacy of SGLT Inhibitors in the Treatment of T1D

10. Why Is SGLT Inhibition Thought to Be Effective in T1D?

11. Dual SGLT Inhibition Glycemia and Other Nonglycemic Parameters

12. inTandem1 Inclusion Criteria and Study Design

13. inTandem1 Baseline Characteristics

14. inTandem1 Change From Baseline in HbA1c Over 52 Weeks*

15. inTandem1 Net Benefit -- Patients With HbA1c < 7
inTandem1 Net Benefit -- Patients With HbA1c < 7.0% at Week 52, Without Severe Hypoglycemia or DKA After Randomization

16. inTandem1 Change From Baseline in Weight Over 52 Weeks

17. Patient-Reported Outcomes inTandem1 Mean Change From Baseline in DDS2 Total Score at Week 52

18. inTandem1 Summary of Safety Outcomes Over 52 Weeks (Safety Population)

19. inTandem1 Acidosis-Related Events Over 52 Weeks

20. Time-in-Range With Sotagliflozin

21. Effect of Sotagliflozin on Daily Insulin Requirements

22. When May Use of SGLT1/SGLT2 Inhibitors in the Treatment of T1D Be Recommended

23. Concluding Remarks

24. Abbreviations

25. Abbreviations (cont)